# Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients

> **NCT04137185** · PHASE1,PHASE2 · COMPLETED · sponsor: **Suzhou Zelgen Biopharmaceuticals Co.,Ltd** · enrollment: 64 (actual)

## Conditions studied

- Differentiated Thyroid Cancer

## Interventions

- **DRUG:** Recombinant Human Thyroid Stimulating Hormone for Injection

## Key facts

- **NCT ID:** NCT04137185
- **Lead sponsor:** Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-10
- **Primary completion:** 2020-12-29
- **Final completion:** 2020-12-29
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2024-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04137185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04137185, "Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04137185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*